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Background: Effectiveness of the wearable cardioverter-defibrillator (WCD) in the prevention of sudden death is dependent on event type, 
compliance and effective treatment of ventricular tachycardia(VT)/fibrillation(VF). We determined patient compliance with and effectiveness of the 
WCD.
Methods: A registry of post-market release WCD users recorded compliance and events. Survival, determined by the Social Security Death Index, 
was compared to 1st implantable cardioverter-defibrillator (ICD) patients.
Results: Of 3569 WCD users (duration 53±70, range 1-1590days), daily use was >90% in 52% (mean 20±5hrs). Longer use correlated with 
higher compliance (p<0.001). Of 80 VT/VF events in 59 patients (1.7%), 1st shock success was 76/76 (100%) for unconscious VT/VF and 79/80 
(99%) for all VT/VF. 8 pts died after successful conversion of VT/VF (survival 89.5% of VT/VF events). Asystole occurred in 23 (17 died), pulseless 
electrical activity in 2 and respiratory arrest in 1 (3 died), representing 24.5% of sudden cardiac arrests (SCA). During WCD use, 99.2% survived 
overall. Survival occurred in 72/80 (90%) VT/VF events and 78/106 (73.6%) for all events. Long-term survival was not significantly different from a 
population of first ICD implant patients.
Conclusions: Compliance was satisfactory with 90% wear time in >50% of patients. Sudden death mortality was 0.78% over a mean 
use of 53 days. Survival was comparable to that of implantable ICD patients, but asystole was an important cause of death in SCA events. 
